Shareholders that lost money on Unicycive Therapeutics, Inc. (UNCY) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

Core Points - The Gross Law Firm is notifying shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit related to misleading statements made by the company during a specified period [1][3] - The class period for the lawsuit is from March 29, 2024, to June 27, 2025, during which the company allegedly overstated its compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [3] - Shareholders are encouraged to register for the class action by October 14, 2025, to potentially recover losses incurred due to the alleged misleading statements [4] Company Allegations - The complaint alleges that Unicycive's readiness to meet FDA manufacturing compliance was overstated [3] - It is claimed that the regulatory prospects for the oxylanthanum carbonate new drug application were also overstated [3] - As a result of these issues, the public statements made by the company were materially false and misleading throughout the relevant time [3] Next Steps for Shareholders - Shareholders who purchased shares during the class period can register to be monitored for updates on the case [4] - There is no cost or obligation for shareholders to participate in the class action [4] - The deadline to seek lead plaintiff status is October 14, 2025 [4]